28.02.2013 • NewsBayerBayer resultsQ4 2012

Bayer 2013 Outlook Slightly Below Market View

Germany's largest drugmaker Bayer gave a 2013 underlying earnings forecast that was slightly below analyst expectations amid competition for one of its most promising new drugs.

Bayer, which celebrates its 150th anniversary this year, said on Thursday it expected growth in adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) in the mid single-digit percentage range, compared with analysts' expectations of about 8%.

A strong rival for Bayer's stroke prevention pill Xarelto has emerged in the form of Bristol Myers-Squibb and Pfizer's Eliquis. The competing product was approved in the United States in December.

That still leaves Bayer's pipeline of new treatments - which includes eye drug Eylea against the leading cause of blindness among the elderly - the envy of many in the industry.

The prospect of future drug sales has shored up its market value including net debt as a multiple of expected core earnings to 7.7, to match the healthcare peer group according to Thomson Reuters StarMine.

That is even though diversified groups like Bayer - also a maker of plastics and farming pesticides - usually trade at a discount to pure-play rivals.

Bayer, the inventor of Aspirin, said it expects its healthcare unit, with its prescription, over-the-counter and animal health drugs, to see sales grow by 6% per year to €22 billion by 2015, excluding currency swings and portfolio changes, up from 18.6 billion in 2012.

Fourth-quarter adjusted EBITDA rose 18.4% to €1.825 billion ($2.39 billion), in line with the average estimate in a Reuters poll.

Quarterly sales of €9.86 billion were slightly above expectations.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.